Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J D Cox

Showing results (181-190 of 185) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 185 results.
Nature Medicine|February 15, 2001
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutationsC M D'Cruz, E J Gunther, R B Boxer, et al.
Journal of the National Cancer Institute|January 15, 1997
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610D J Grignon, R Caplan, F H Sarkar, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2000
Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406J M Michalski, J A Purdy, K Winter, et al.
Annals of Internal Medicine|July 21, 1998
A multidisciplinary approach to therapy for unresectable malignant thymomaD M Shin, G L Walsh, R Komaki, et al.
Seminars in Radiation Oncology|March 28, 2002
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary resultsR Komaki, J S Lee, B Kaplan, et al.
Pageof 19

Showing results (181-190 of 185) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 185 results.
Nature Medicine|February 15, 2001
c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutationsC M D'Cruz, E J Gunther, R B Boxer, et al.
Journal of the National Cancer Institute|January 15, 1997
p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610D J Grignon, R Caplan, F H Sarkar, et al.
International Journal of Radiation Oncology, Biology, Physics|February 8, 2000
Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406J M Michalski, J A Purdy, K Winter, et al.
Annals of Internal Medicine|July 21, 1998
A multidisciplinary approach to therapy for unresectable malignant thymomaD M Shin, G L Walsh, R Komaki, et al.
Seminars in Radiation Oncology|March 28, 2002
Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: preliminary resultsR Komaki, J S Lee, B Kaplan, et al.
Pageof 19